Structure Explains Severity: How Multimers Transformed von Willebrand Disease

Prev
 1 / 21 
Next
Prev
 1 / 21 
Next

Learning objectives

After completing this quiz, the learner should be able to:

  • Explain why VWF quantity alone cannot account for bleeding severity.
  • Describe how multimer analysis transformed the understanding and classification of VWD.
  • Interpret the relationship between VWF:Ag, platelet-dependent VWF activity, and the platelet-dependent activity/VWF:Ag ratio.
  • Distinguish quantitative from qualitative VWD using laboratory patterns.
  • Apply multimer findings to differentiate major type 2 VWD subtypes.
  • Recognize how molecular architecture helps explain bleeding phenotype.
  • Integrate structural biology with clinical reasoning when evaluating patients with suspected VWD.

Which advance most directly transformed von Willebrand disease from a disorder understood primarily in terms of quantity into one understood through molecular architecture?

a
Development of FVIII:C assays
FVIII:C assays improved diagnosis and helped distinguish VWD from hemophilia A but did not reveal VWF architecture.
b
Development of VWF:Ag assays
VWF:Ag assays measured the amount of VWF present but could not distinguish structurally abnormal molecules from normal ones.
c
Multimer analysis demonstrating abnormal VWF structure across clinically distinct VWD variants
The introduction of VWF multimer analysis, pioneered by investigators including Ruggeri and Zimmerman, showed that patients with similar VWF concentrations could have markedly different molecular structures. This transformed VWD from a disorder defined primarily by the amount of VWF into one understood through distinct structural and functional mechanisms.
d
Routine genetic sequencing of the VWF gene
Genetic testing further refined classification but came years after multimer analysis had already established the importance of molecular architecture.

A patient has the following laboratory results:

  • VWF:Ag: 60 IU/dL
  • Platelet-dependent VWF activity: 30 IU/dL

Which interpretation is most appropriate?

a
The platelet-dependent activity/VWF:Ag ratio raises concern for a qualitative VWF defect.
A platelet-dependent activity/VWF:Ag ratio below approximately 0.7 suggests that VWF function is disproportionately impaired relative to its concentration. This raises concern for a qualitative defect such as type 2 VWD, although interpretation always depends on the assay used, laboratory standards, and clinical context.
b
The patient most likely has a simple quantitative deficiency.
A quantitative deficiency would typically produce proportional reductions in antigen and platelet-dependent activity.
c
The VWF:Ag excludes clinically significant VWD.
Patients with qualitative VWD may have only mildly reduced or even normal VWF:Ag despite clinically significant bleeding.
d
These results cannot be interpreted without genetic testing.
Genetic testing may be helpful in selected patients but is not required to recognize this laboratory pattern.

What information does VWF multimer analysis primarily provide?

a
The plasma concentration of VWF
VWF:Ag measures plasma concentration.
b
The amount of FVIII bound to VWF
FVIII binding is assessed with specialized VWF:FVIII-binding assays rather than multimer analysis.
c
The degree of platelet activation
Multimer analysis evaluates VWF structure rather than platelet activation.
d
The distribution of VWF molecules according to molecular size
VWF multimer analysis separates VWF molecules by agarose gel electrophoresis, producing a ladder of bands according to molecular size. The resulting pattern demonstrates whether low-, intermediate-, and high-molecular-weight multimers are preserved, selectively lost, or otherwise abnormal, providing insight into VWF architecture rather than simply its concentration.

Two patients both have reduced platelet-dependent VWF activity and loss of high-molecular-weight multimers.

Patient A

  • Mild thrombocytopenia
  • Increased low-dose RIPA

Patient B

  • Normal platelet count
  • Normal low-dose RIPA

Which interpretation is most appropriate?

a
Patient A has type 2A VWD and Patient B has type 2B VWD.
The laboratory patterns are reversed.
b
Both patients most likely have type 2M VWD.
Type 2M VWD generally preserves high-molecular-weight multimers.
c
Patient A is more consistent with type 2B VWD, whereas Patient B is more consistent with type 2A VWD.
Both patients have loss of high-molecular-weight multimers, but increased low-dose RIPA and thrombocytopenia strongly suggest type 2B VWD because of enhanced platelet binding. The absence of these findings is more consistent with type 2A VWD, in which defective multimer assembly or increased proteolysis causes multimer loss without increased platelet binding.
d
Multimer analysis cannot distinguish these disorders.
When combined with platelet count and low-dose RIPA, multimer analysis provides important clues to subtype classification.

Which mechanism best explains type 2A VWD?

a
Defective multimer assembly or increased ADAMTS13-mediated proteolysis leading to loss of high-molecular-weight multimers
Type 2A VWD is characterized by selective loss of high-molecular-weight multimers because of defective multimer assembly, impaired secretion, increased susceptibility to ADAMTS13-mediated proteolysis, or a combination of these mechanisms. The resulting loss of the largest multimers impairs platelet-dependent function despite measurable VWF.
b
Increased affinity of VWF for platelet GPIbα
Reduced synthesis of structurally normal VWF is characteristic of type 1 VWD.
c
Increased affinity of VWF for platelet GPIbα
Increased affinity for platelet GPIbα defines type 2B VWD.
d
Impaired binding of VWF to factor VIII
Impaired FVIII binding is the hallmark of type 2N VWD.

A patient has the following laboratory findings:

  • VWF:Ag: 42 IU/dL
  • Platelet-dependent VWF activity: 18 IU/dL
  • High-molecular-weight multimers preserved

Which diagnosis is most consistent with this pattern?

a
Type 1 VWD
Type 1 VWD typically produces proportionate reductions in VWF:Ag and platelet-dependent activity, with a normal activity-to-antigen ratio and preserved multimers.
b
Type 2A VWD
Type 2A VWD is characterized by loss of high-molecular-weight multimers.
c
Type 2M VWD
Type 2M VWD is characterized by impaired platelet-dependent VWF function despite preservation of high-molecular-weight multimers. The defect lies in VWF function rather than multimer assembly or survival.
d
Type 2B VWD
Type 2B VWD usually demonstrates increased low-dose RIPA and often thrombocytopenia because of enhanced platelet binding.

A patient demonstrates increased agglutination on low-dose RIPA and loss of high-molecular-weight multimers.

Which additional study is most useful for distinguishing type 2B VWD from platelet-type VWD?

a
VWF:Ag
VWF:Ag does not distinguish these disorders.
b
FVIII:C
FVIII:C is generally not discriminatory.
c
VWF multimer analysis
Both disorders may demonstrate similar multimer abnormalities.
d
RIPA mixing studies and/or genetic testing
Type 2B VWD and platelet-type VWD produce similar clinical and laboratory findings because both result in increased VWF-platelet interactions. RIPA mixing studies and/or genetic testing determine whether the gain-of-function defect resides in VWF (type 2B VWD) or platelet GPIb (platelet-type VWD).

An 80-year-old man with severe calcific aortic stenosis develops recurrent gastrointestinal bleeding.

Laboratory studies demonstrate loss of high-molecular-weight VWF multimers.

Which mechanism best explains these findings?

a
Reduced endothelial synthesis of VWF
VWF synthesis is generally normal.
b
High shear unfolds VWF, increasing susceptibility to ADAMTS13-mediated proteolysis.
High shear forces across a severely stenotic aortic valve unfold VWF, exposing the A2 domain cleavage site to ADAMTS13. Enhanced proteolysis removes high-molecular-weight multimers, producing an acquired von Willebrand syndrome that resembles congenital type 2A VWD because the structural consequence is similar.
c
Congenital type 2A VWD
The mechanism is acquired rather than inherited.
d
Autoimmune destruction of VWF
The defect results from mechanical shear rather than immune-mediated destruction.

During arterial blood flow, shear stress causes VWF to unfold.

Why is this conformational change biologically important?

a
It permanently activates VWF.
Activation is transient and tightly regulated by ADAMTS13.
b
It increases endothelial synthesis of VWF.
Shear changes VWF conformation, not its synthesis.
c
It promotes platelet adhesion while simultaneously exposing the ADAMTS13 cleavage site.
VWF is a mechanosensitive protein. Shear-induced unfolding exposes adhesive domains that support platelet binding while simultaneously revealing the A2 domain cleavage site recognized by ADAMTS13. Thus, the same structural transition both activates and regulates VWF, helping maintain the balance between hemostasis and thrombosis.
d
It prevents proteolytic regulation of VWF.
Unfolding facilitates rather than prevents ADAMTS13-mediated cleavage.

A trainee summarizes the lesson of the multimer era by saying:

“Patients with the same VWF:Ag level may bleed differently because their VWF molecules are built differently.”

Which response is most accurate?

a
Correct. Molecular architecture helps explain differences in VWF function and bleeding phenotype.
This statement captures the central message of the essay. Modern understanding of VWD integrates quantity, molecular architecture, function, and regulation. Multimer analysis demonstrated that patients with similar VWF concentrations may have markedly different structural defects, explaining differences in laboratory findings and bleeding severity.
b
Incorrect. Bleeding severity depends only on the amount of VWF present.
Quantity alone cannot account for many qualitative forms of VWD.
c
Incorrect. Structural abnormalities are important only in type 3 VWD.
Structural abnormalities are fundamental to the type 2 variants.
d
Incorrect. Multimer analysis has largely been replaced by genetic testing.
Although genetic testing is valuable in selected patients, multimer analysis remains an important tool for understanding VWF structure and classifying qualitative VWD.

Sort each feature into the most appropriate category.

Type 2N VWD
Type 2M VWD
Platelet-dependent activity/VWF:Ag ratio below approximately 0.7
Proportionate reduction in VWF:Ag and platelet-dependent activity
Preserved high-molecular-weight multimers despite reduced platelet-dependent activity
Type 1 VWD
Loss of high-molecular-weight multimers
Defective FVIII binding
ADAMTS13 cleaves unfolded VWF
VWF unfolds under shear stress
Type 2A VWD
Increased low-dose RIPA
Quantitative deficiency
Qualitative structural or functional defect
Dynamic regulation of VWF

Match each laboratory pattern or clinical finding with the interpretation it most strongly suggests.

Loss of high-molecular-weight multimers
Platelet-dependent activity/VWF:Ag ratio below approximately 0.7
Proportionate reduction in VWF:Ag and platelet-dependent activity
Qualitative VWF defect
Structural abnormality
Quantitative deficiency
Correct! Sorry, Incorrect.

Match each laboratory pattern or clinical finding with the interpretation it most strongly suggests.

Preserved multimers with reduced platelet-dependent activity
Gain-of-function defect in platelet GPIb
Increased low-dose RIPA
Platelet-type VWD
Type 2B VWD
Type 2M VWD
Correct! Sorry, Incorrect.

Key takeaways

  • VWF quantity alone cannot explain bleeding severity.
  • Multimer analysis transformed VWD from a disorder of amount into one of molecular architecture.
  • The platelet-dependent activity/VWF:Ag ratio helps distinguish quantitative from qualitative VWF defects.
  • High-molecular-weight multimers are the most effective forms of VWF for platelet adhesion under conditions of high shear.
  • Multimer analysis helps distinguish major type 2 VWD subtypes by revealing different structural patterns.
  • VWF is a dynamic, mechanosensitive protein whose function is regulated by shear stress and ADAMTS13.
  • Modern diagnosis integrates quantity, structure, function, and clinical phenotype to explain why patients with similar VWF levels may bleed very differently.

Closing Note

The discovery of VWF multimers transformed the understanding of von Willebrand disease by revealing that structure matters as much as quantity. Modern clinicians no longer ask only “How much VWF is present?” They also ask “How is VWF built, how does it function, and how is it regulated?” Answering those questions connects laboratory findings with biological mechanism and ultimately helps explain why patients with seemingly similar VWF levels can experience very different bleeding phenotypes.

Prev
 1 / 21 
Next